Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil.
The VIPoma syndrome is rare. It is usually caused by a neuroendocrine tumor located in the pancreas. Somatostatin analogs and interferon-a can be helpful in the symptomatic control of the disease, but the efficacy of chemotherapy in metastatic disease is limited. We report the case of a 32-yr-old patient who had a primary intestinal VIPoma with peritoneal carcinomatosis and hepatic metastases. Somatostatin analogs and conventional chemotherapy regimens were not effective on VIPoma syndrome and tumor progression. The combination of 5- fluorouracil and interferon-alpha was associated with a major clinical improvement and tumor regression. Further investigations should evaluate the place of such a combination as a first line treatment for patients with metastatic neuroendocrine tumors.
Cellier
C
C
Department of Hepato-gastroenterology, Laennec Hospital, Paris, France.
Yaghi
C
C
Cuillerier
E
E
Siauve
N
N
Berger
A
A
Carnot
F
F
Haddad
C
C
Barbier
J P
JP
Landi
B
B
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007580:Jejunal Neoplasms / Q000473:pathology*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D008297:Male; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D014057:Tomography, X-Ray Computed; D003969:Vipoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*
D016898:Interferon-alpha; D005472:Fluorouracil